AU7130101A - Enzyme-cleavable prodrug compounds - Google Patents

Enzyme-cleavable prodrug compounds

Info

Publication number
AU7130101A
AU7130101A AU7130101A AU7130101A AU7130101A AU 7130101 A AU7130101 A AU 7130101A AU 7130101 A AU7130101 A AU 7130101A AU 7130101 A AU7130101 A AU 7130101A AU 7130101 A AU7130101 A AU 7130101A
Authority
AU
Australia
Prior art keywords
enzyme
prodrug compounds
cleavable prodrug
cleavable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU7130101A
Inventor
Matthew H Nieder
Vincent Dubois
Sanjeev Gangwar
Thomas J Lobl
Leslie B Pickford
Andre Trouet
Geoffrey T Yarranton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU7130101A publication Critical patent/AU7130101A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU7130101A 2000-06-14 2001-06-11 Enzyme-cleavable prodrug compounds Pending AU7130101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21188700P 2000-06-14 2000-06-14
US29044801P 2001-05-11 2001-05-11
PCT/US2001/018903 WO2001095945A2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase

Publications (1)

Publication Number Publication Date
AU7130101A true AU7130101A (en) 2001-12-24

Family

ID=26906558

Family Applications (2)

Application Number Title Priority Date Filing Date
AU7130101A Pending AU7130101A (en) 2000-06-14 2001-06-11 Enzyme-cleavable prodrug compounds
AU2001271301A Ceased AU2001271301B2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001271301A Ceased AU2001271301B2 (en) 2000-06-14 2001-06-11 Prodrug compounds cleavable by thimet oligopeptidase

Country Status (5)

Country Link
EP (1) EP1294405A2 (en)
JP (1) JP2004510703A (en)
AU (2) AU7130101A (en)
CA (1) CA2411660C (en)
WO (1) WO2001095945A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030033007A (en) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
DE60239679D1 (en) * 2001-06-11 2011-05-19 Medarex Inc METHOD FOR MACHINING CD10-ACTIVATED PRODRUG COMPOUNDS
FR2858936A1 (en) * 2003-08-22 2005-02-25 Diatos New active compound precursor, useful as therapeutic or diagnostic agent or tracer, includes cleavable component that increases half-life in the circulation, attached through hydrophilic spacer
TWI447124B (en) 2006-12-01 2014-08-01 Medarex Llc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
IN2009KN02404A (en) 2006-12-14 2015-08-07 Medarex Inc
DE102008007381A1 (en) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidines and guanidines and their derivatives for the treatment of diseases
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
WO2014147124A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
EP4267188A1 (en) 2020-12-22 2023-11-01 Cobiores NV Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535665T2 (en) * 1994-08-19 2009-04-02 La Region Wallonne CONJUGATES CONTAIN AN ANTITUMORAL AGENT AND ITS USE
IL143666A0 (en) * 1998-12-11 2002-04-21 Coulter Pharm Inc Prodrug compounds and process for preparation thereof

Also Published As

Publication number Publication date
CA2411660C (en) 2011-03-01
WO2001095945A3 (en) 2002-08-15
AU2001271301B2 (en) 2006-08-31
WO2001095945A2 (en) 2001-12-20
CA2411660A1 (en) 2001-12-20
EP1294405A2 (en) 2003-03-26
JP2004510703A (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU7552501A (en) Tripeptide prodrug compounds
GB0107758D0 (en) Anti-cancer compounds
AU6685301A (en) Prodrug compounds with isoleucine
EP1349851A4 (en) Compounds
AU7130101A (en) Enzyme-cleavable prodrug compounds
AU2405002A (en) Dehalogeno compounds
GB0027552D0 (en) Anti-tumor compounds
GB0028105D0 (en) Compounds
AU2002221812A1 (en) Fap-activated anti-tumour prodrug
GB0007636D0 (en) Anti-cancer compounds
GB0015117D0 (en) Anti-cancer compounds
GB0027551D0 (en) Anti-tumor compounds
GB0014642D0 (en) Compounds
GB0006797D0 (en) Compounds
GB0020503D0 (en) Compounds
GB0018351D0 (en) Compounds
GB0018306D0 (en) Compounds
GB0015902D0 (en) Compounds
GB0015863D0 (en) Compounds
GB0003140D0 (en) Compounds
GB0015852D0 (en) Compounds
GB0014823D0 (en) Compounds
GB0014652D0 (en) Compounds
GB0023193D0 (en) Compounds
GB0014641D0 (en) Compounds